Last reviewed · How we verify
Gabapentin 300 mg
At a glance
| Generic name | Gabapentin 300 mg |
|---|---|
| Also known as | Darbetin®, Laboratorios Dermatologicos Darier, Nerotin®, Pfizer |
| Sponsor | St. Louis University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Pregabalin Versus Gabapentin as Pre-emptive Analgesic (NA)
- Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients (PHASE4)
- Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia (PHASE3)
- Pregabalin vs. Gabapentin on Reducing Opioid Usage (PHASE4)
- Gabapentin and Neural Mobilization Pain Reduction Effect Compared to Only Gabapentine (PHASE4)
- Pain Reduction Caused by the Combined Treatment of Physiotherapy, Oral Gabapentin and Oral Ibuprofen Arginine. (PHASE4)
- Pain Reduction and Changes in Upper Limb Function Produced by Different Treatments in Carpal Tunnel Syndrome (PHASE4)
- Oral Gabapentin and Median Nerve Mobilization in the Treatment of Carpal Tunnel Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gabapentin 300 mg CI brief — competitive landscape report
- Gabapentin 300 mg updates RSS · CI watch RSS
- St. Louis University portfolio CI